Garen Bohlin Biography and Net Worth

Garen Bohlin held senior executive positions with biotechnology companies for almost 30 years. In his final operating role, Mr. Bohlin was Executive Vice President of Constellation Pharmaceuticals. Previously, he served as Chief Operating Officer of Sirtris Pharmaceuticals (acquired by GlaxoSmithKline). Prior to Sirtris, he was President and Chief Executive Officer of Syntonix Pharmaceuticals (acquired by Biogen).

Prior to Syntonix, Mr. Bohlin served as Executive Vice President of Genetics Institute (acquired by American Home Products/Wyeth). Mr. Bohlin currently serves on the board of directors of Karyopharm Therapeutics, Inc. (KPTI). Previously, he served on the board of directors of Acusphere, Inc. (ACUS), Proteon Therapeutics, Inc. (PRTO), Tetraphase Pharmaceuticals, Inc. (TTPH) and several other publicly traded and privately held biotechnology companies.

What is Garen G. Bohlin's net worth?: The estimated net worth of Garen G. Bohlin is at least $1.20 million as of May 14th, 2024. Bohlin owns 44,775 shares of Collegium Pharmaceutical stock worth more than $1,199,522 as of April 27th. This net worth estimate does not reflect any other assets that Bohlin may own. Learn More about Garen G. Bohlin's net worth.
How do I contact Garen G. Bohlin?: The corporate mailing address for Bohlin and other Collegium Pharmaceutical executives is 100 Technology Center Drive, Stoughton MA, 02072. Collegium Pharmaceutical can also be reached via phone at (781) 713-3699 and via email at info@collegiumpharma.com. Learn More on Garen G. Bohlin's contact information.
Has Garen G. Bohlin been buying or selling shares of Collegium Pharmaceutical?: Garen G. Bohlin has not been actively trading shares of Collegium Pharmaceutical within the last three months. Most recently, Garen G. Bohlin sold 28,985 shares of the business's stock in a transaction on Tuesday, May 14th. The shares were sold at an average price of $32.30, for a transaction totalling $936,215.50. Following the completion of the sale, the director now directly owns 44,775 shares of the company's stock, valued at $1,446,232.50. Learn More on Garen G. Bohlin's trading history.
Who are Collegium Pharmaceutical's active insiders?: Collegium Pharmaceutical's insider roster includes Garen Bohlin (Director), Joseph Ciaffoni (CEO), Joseph Ciaffoni (Pres), Scott Dreyer (EVP), Michael Heffernan (Director), Shirley Kuhlmann (EVP), Thomas Smith (EVP), Colleen Tupper (CFO), and Colleen Tupper (Exec. VP & CFO ). Learn More on Collegium Pharmaceutical's active insiders.
Are insiders buying or selling shares of Collegium Pharmaceutical?: During the last year, insiders at the specialty pharmaceutical company sold shares 12 times. They sold a total of 243,536 shares worth more than $7,872,884.47. The most recent insider tranaction occured on March, 14th when CFO Colleen Tupper sold 977 shares worth more than $29,310.00. Insiders at Collegium Pharmaceutical own 2.5% of the company. Learn More about insider trades at Collegium Pharmaceutical.
Information on this page was last updated on 3/14/2025.

Garen G. Bohlin Insider Trading History at Collegium Pharmaceutical

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
5/14/2024	Sell	28,985	$32.30	$936,215.50	44,775

Garen G. Bohlin Buying and Selling Activity at Collegium Pharmaceutical

Collegium Pharmaceutical Company Overview

Collegium Pharmaceutical, Inc., a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, and oral formulation of oxycodone for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol, indicated for the management of acute, severe, and persistent pain; Belbuca, a buccal film that contains buprenorphine; and Symproic, an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain. The company was formerly known as Collegium Pharmaceuticals, Inc. and changed its name to Collegium Pharmaceutical, Inc. in October 2003. Collegium Pharmaceutical, Inc. was incorporated in 2002 and is headquartered in Stoughton, Massachusetts.

Today's Range

Now: $26.79

$26.22

$27.09

50 Day Range

MA: $28.40

$24.67

$30.56

2 Week Range

Now: $26.79

$23.23

$42.29

Volume

214,645 shs

Average Volume

444,130 shs

Market Capitalization

$860.82 million

P/E Ratio

11.55

Dividend Yield

N/A

Beta

0.76